Lennox–Gastaut syndrome

Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Monday, March 13, 2023

To support this strategy, Ovid instituted cost-cutting measures that began in 2022 and continue into this year.

Key Points: 
  • To support this strategy, Ovid instituted cost-cutting measures that began in 2022 and continue into this year.
  • In addition, Ovid is eligible to receive non-dilutive capital from Takeda, if and when soticlestat is successfully approved and marketed.
  • Business development strategy: Ovid intends to conduct disciplined business development activities with a focus on clinical stage assets and enabling technologies to complement its portfolio of anti-seizure medicines.
  • The annual decrease was a result of the above mentioned cost cutting and personnel reduction efforts undertaken in 2022.

For Rare Disease Day, Behind the Mystery of Lennox-Gastaut Syndrome is airing on Lifetime TV February 20th and 28th

Retrieved on: 
Thursday, February 16, 2023

Click here to learn more about how YOU can watch the show, which will air again on Rare Disease Day, February 28, 2023 .

Key Points: 
  • Click here to learn more about how YOU can watch the show, which will air again on Rare Disease Day, February 28, 2023 .
  • LGS is a severe rare disease that starts in infancy and early childhood with uncontrolled seizures and quickly leads to a lifetime of disability in these children.
  • Through this work, the LGS Foundation is empowering the community to advocate and take a stand against LGS.
  • Behind the Mystery and LGS Foundation are aligned with our devotion to the rare disease community, elevating the voice of the voiceless on Rare Disease Day and everyday," says Carri Levy, Creator of Behind the Mystery.

Jazz Pharmaceuticals receives NICE recommendation for the reimbursement of Epidyolex® (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex in England

Retrieved on: 
Tuesday, January 31, 2023

TSC can be diagnosed in infancy but many children are not diagnosed until later in childhood when their seizures begin and other symptoms appear.

Key Points: 
  • TSC can be diagnosed in infancy but many children are not diagnosed until later in childhood when their seizures begin and other symptoms appear.
  • [4] It is estimated that between 3,700 and 11,000 people in the UK live with TSC.
  • TSC is a very difficult to manage condition, with common issues including epilepsy in eight out of ten people.
  • Please note that, in relation to this Jazz media announcement, no honorarium was provided to the Tuberous Sclerosis Association.

Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments

Retrieved on: 
Wednesday, February 8, 2023

Dr. Malhotra brings to Ovid deep expertise from his career serving as a clinical trialist, a treating epileptologist, and a senior medical affairs executive within biopharmaceutical companies.

Key Points: 
  • Dr. Malhotra brings to Ovid deep expertise from his career serving as a clinical trialist, a treating epileptologist, and a senior medical affairs executive within biopharmaceutical companies.
  • He joins us from senior roles at global pharmaceutical companies where he contributed to the development and approval of multiple neurological medicines,” said Jeremy Levin, D. Phil, MB BChir, Chairman and Chief Executive Officer of Ovid Therapeutics.
  • He joins Ovid from Takeda Pharmaceuticals, where he played a critical role in the invention and development of soticlestat, a small molecule inhibitor of cholesterol 24-hydroxylase.
  • At Ovid, he will support preclinical development, including a dedicated focus on the KCC2 program.

Assertio Announces Partnership with the Lennox-Gastaut Syndrome (LGS) Foundation

Retrieved on: 
Tuesday, January 17, 2023

LAKE FOREST, Ill., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it has provided the LGS Foundation a $100,000 educational grant to assist in efforts to raise awareness of LGS and provide educational materials to the LGS community.

Key Points: 
  • According to the LGS Foundation, Lennox-Gastaut Syndrome or LGS is a severe epilepsy syndrome.
  • It is generally diagnosed between the ages of 3 and 5, but some people aren’t correctly diagnosed until much later.
  • “Assertio is dedicated to being a great partner to the LGS community,” said Dan Peisert, President and Chief Executive Officer of Assertio.
  • We look forward to a long and collaborative partnership.”
    In addition to supporting the LGS Foundation’s educational mission, Assertio will also be joining the organization’s Corporate Advisory Council.

Virpax Pharmaceuticals Reports on FDA Pre-IND Response for NobrXiol™ (formerly VRP324)

Retrieved on: 
Wednesday, December 14, 2022

Virpax now has guidance on how to proceed with the IND enabling studies and possible regulatory pathways to pursue for NobrXiol, stated Dr. Sheila A. Mathias, Chief Scientific Officer for Virpax.

Key Points: 
  • Virpax now has guidance on how to proceed with the IND enabling studies and possible regulatory pathways to pursue for NobrXiol, stated Dr. Sheila A. Mathias, Chief Scientific Officer for Virpax.
  • This is a significant step forward for the NobrXiol project and we are very pleased with the outcome of the pre-IND meeting with the FDA, said Anthony P. Mack, Chairman and CEO of Virpax.
  • Virpax is developing branded product candidates for non-addictive pain management and neurological disorders using its proprietary technologies that optimize and target drug delivery.
  • Virpax is initially seeking FDA approval of its three different patented drug delivery platforms.

Cannabis Cultivation Global Market Report 2022: Increasing Use of Cannabis as a Treatment for Chronic Disease Boosts Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, December 5, 2022

The regions covered in the cannabis cultivation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Key Points: 
  • The regions covered in the cannabis cultivation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • Adoption of cannabis for the treatment of chronic diseases is expected to propel the growth of the cannabis cultivation market going forward.
  • Therefore, the adoption of cannabis for the treatment of chronic diseases is driving the cannabis cultivation market.
  • Major companies operating in the cannabis cultivation market are focused on developing innovative products to strengthen their position in the cannabis cultivation market.

Longboard Pharmaceuticals Announces Positive Topline Data from a Phase 1 Clinical Study Evaluating Central Nervous System Pharmacokinetics and Pharmacodynamics of LP352 in Healthy Volunteers

Retrieved on: 
Monday, December 5, 2022

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive topline results from a Phase 1 clinical study evaluating the central nervous system (CNS) pharmacokinetics (PK) and pharmacodynamics (PD) of LP352, an oral, centrally acting 5-HT2C superagonist, in healthy volunteers.

Key Points: 
  • Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive topline results from a Phase 1 clinical study evaluating the central nervous system (CNS) pharmacokinetics (PK) and pharmacodynamics (PD) of LP352, an oral, centrally acting 5-HT2C superagonist, in healthy volunteers.
  • The primary objectives of this open-label, Phase 1 study are to assess the CNS PK and PD of orally administered LP352 in healthy adult male and female participants (n=10 in each Cohort).
  • At steady state, LP352 12 mg TID mean concentrations exceeded the Ki value for 5-HT2C activity throughout the dosing interval.
  • Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)

Retrieved on: 
Friday, December 2, 2022

If successful, these programs will provide hope for people with treatment-resistant epilepsies, said Jeremy Levin, D. Phil, MB BChir and Chairman and Chief Executive Officer of Ovid Therapeutics.

Key Points: 
  • If successful, these programs will provide hope for people with treatment-resistant epilepsies, said Jeremy Levin, D. Phil, MB BChir and Chairman and Chief Executive Officer of Ovid Therapeutics.
  • Our pipeline of potential medicines is designed with unique mechanisms of action to address the diverse, underlying pathophysiology of seizures.
  • Our data suggest OV329 to be a potent, next-generation GABA-AT inhibitor with the potential for seizure reduction with chronic, low dosing.
  • Data presented on OV350 support the therapeutic opportunity associated with activating KCC2, a novel target in epilepsy.

NeuroPace Feasibility Study of Its RNS System for Lennox-Gastaut Syndrome Now Underway

Retrieved on: 
Wednesday, November 30, 2022

An exciting aspect of this study is that the implant location for each patient is based on customized models of their brain connectivity.

Key Points: 
  • An exciting aspect of this study is that the implant location for each patient is based on customized models of their brain connectivity.
  • Six study sites will enroll a total of 20 patients 12 years of age and older with LGS and drug-resistant generalized onset seizures.
  • [i]
    The RNS System, a paradigm-shifting treatment for drug-resistant focal epilepsy, is the only brain-responsive neuromodulation system approved by the FDA.
  • The RNS System is available at most comprehensive epilepsy centers in the United States and is widely covered by insurance.